Presentation is loading. Please wait.

Presentation is loading. Please wait.

Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,

Published bySandra Anthony Modified over 9 years ago

Similar presentations

Presentation on theme: "Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,"— Presentation transcript:

1 Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo, Egypt rrawson@mednet.ucla.edu www.uclaisap.org

2

3 Potentially lethal dose Positive effect = addictive potential Negative effect Full agonist- morphine/heroin hydromorphone Antagonist - naltrexone dose Antagonist + agonist/partial agonist Agonist + partial agonist Super agonist- fentanyl Partial agonist - buprenorphine Mu efficacy and opiate addiction

4 Buprenorphine: Clinical Pharmacology Partial Agonist high safety profile/ceiling effect low dependence Tight Receptor Binding long duration of action slow onset mild abstinence

5 Good Effect

6 Respiration

7 Intensity of abstinence 60 50 40 30 20 10 0 Himmelsbach scores 012345678910111213141516171819202122 Buprenorphine Morphine Days after drug withdrawal

8 Buprenorphine detoxification in community clinics Buprenorphine : Very brief pharmacology CTN Protocols 0001 & 0002 Buprenorphine vs clonidine: Inpatient detoxification Outpatient detoxification Treatment success /Number needed to treat Looking ahead: Implementation: Successes and barriers The rest of the world

9 The First CTN Protocols Short term inpatient detoxification –Buprenorphine/naloxone vs clonidine –(CTN 0001) Short term outpatient detoxification –Buprenorphine/naloxone vs clonidine –(CTN 0002)

10 Study Design Buprenorphine/Naloxone 13 days detoxification Open Randomized Study Bup/Nx:Clonidine = 2:1 Clonidine 13 days detoxification

11 Joint Probability N remaining in treatment X Total N of subjects N giving drug free urines N remaining in treatment

12 Demographics 0001 (Inpatient) Bup/NxClonidineTotal Sex No. (%) Male Female 47 (61) 30 (39) 21 (58) 15 (42) 68 (60) 45 (40) Race No. (%) White Black Hispanic Other 43 (56) 15 (19) 12 (16) 7 (9) 20 (56) 7 (19) 6 (17) 3 (8) 63 (56) 22 (19) 18 (16) 10 (9) Age in Years: Mean (Range 21-61) 35.637.4- Employment % (full/part time)--66 Mean Education in Years (SD)--12.8 (1.7) Mean Years of Heroin Use (SD)--6.6 (8.1)

13 Present and Clean 0001 (Inpatient) Present and Opiate Clean Bup/Nx%Clonidine% N 7736 Day 3 or 45267.51644.4 Day 7 or 86381.81336.1 Day 10 or 115672.71027.8 Day 13 or 145976.6822.2

14 Percent Present and Clean 0001 (Inpatient)

15 Demographics 0002 (Outpatient) Bup/NxClonidineTotal Sex No. (%) Male Female 115 (73) 42 (27) 51 (69)) 23 (31) 166 (72) 65 (28) Race No. (%) White Black Hispanic Other 62 (40) 57 (36) 33 (21) 5 (3) 30 (40) 28 (38) 13 (18) 3 (4) 92 (40) 85 (37) 46 (20) 8 (3) Age in Years: Mean (Range 21-61) 38.340.0- Employment % (full/part time)--56.8 Mean Education in Years (SD)--12.4 (2.1) Mean Years of Heroin Use (SD)--9.42 (9.6)

16 Present and Clean 0002 (Outpatient) Present and Opiate Clean Bup/Nx%Clonidine% N 15774 Day 3 or 43723.656.8 Day 7 or 85635.768.1 Day 10 or 115233.156.8 Day 13 or 144629.345.4

17 Percent Present and Clean 0002 (Outpatient)

18 NNT: Number Needed to Treat CTN 0001 (Inpatient) NNT for Bup/Nx 77/59 = 1.31 NNT for Clonidine 36/8 = 4.5 NNT Clonidine : BupNx = 3.44 CTN 0002 (Outpatient) NNT for Bup/Nx: 157/46 = 3.4 NNT for Clonidine: 74/4 = 18.5 NNT Clonidine : Bup/Nx = 5.44 NNT= Number of patients needed to treat to achieve 1 treatment success

19 Buprenorphine: what does it really mean? The great social experiment: return of opioid addiction treatment to medicine Slow progress in implementation: –External barriers: legislative compromises –Inertia and resistance: medication and recovery Application to the world and the region

20 Pharmacotherapy and Recovery Medications and recovery: incompatible? “Medication is not recovery” The great chemistry paradox –Addiction: chemistry went wrong –Role of “chemistry” (medicine) in recovery

21 You Can Change the Brain with Either Biological or Behavioral Treatments Remember…. Alan Leshner

22 How People Change “You can change some one’s life by altering his genes; but you can also do that by paying off his credit card” James Watson

23 Thanks to XIII Congress of Psychiatry: symposia organizing committee National Institute on Drug Abuse NIDA Clinical Trials Network Staff CTN Publications Committee Participating CTN Nodes and CTPs Reckitt Benckiser: supplier of study med Participating Patients You the audience

Download ppt "Buprenorphine and the NIDA CTN: Research to Practice Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo,"

Similar presentations

13 Principles of Effective Addictions Treatment

13 Principles of Effective Addictions Treatment
XR-NTX Implementation in Los Angeles County Desirée A. Crèvecoeur-MacPhail, PhD UCLA Integrated Substance Abuse Programs 11075 Santa Monica Blvd., Suite.

XR-NTX Implementation in Los Angeles County Desirée A. Crèvecoeur-MacPhail, PhD UCLA Integrated Substance Abuse Programs Santa Monica Blvd., Suite.
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.

Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
What is the evidence for time limiting addiction treatment?

What is the evidence for time limiting addiction treatment?
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.

Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Karran A. Phillips, MD, MSc NIDA Intramural Research Program AMERSA Annual Meeting November 8, 2014.

Karran A. Phillips, MD, MSc NIDA Intramural Research Program AMERSA Annual Meeting November 8, 2014.
Sublingual Buprenorphine and Pain

Sublingual Buprenorphine and Pain
Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,

Comparative Effectiveness Research in the National Drug Abuse Treatment Clinical Trials Network (CTN) CDR Steven Sparenborg, Ph.D., Udi Ghitza, Ph.D.,
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
Opioid Dependence: Treatment Options Walter Ling MD Integrated Substance Abuse Programs(ISAP) UCLA Suboxone Advisory Board Meeting Kaohsiung, Taiwan November.

Opioid Dependence: Treatment Options Walter Ling MD Integrated Substance Abuse Programs(ISAP) UCLA Suboxone Advisory Board Meeting Kaohsiung, Taiwan November.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.

Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse.

Hypermed, Inc.’s Patent-Pending Advanced Rapid Opiate Detox Protocol Stopping addiction in 8 hours without withdrawal and without relapse.
Buprenorphine : A New Approach for Opioid Treatment Thomas E. Freese, Ph.D. Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance.

Buprenorphine : A New Approach for Opioid Treatment Thomas E. Freese, Ph.D. Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.

Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA 016237 (PI: Kinlock)

Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist’s Courses A Generalist’s Course Developed by the Mountain.

BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) For Infusion Into Undergraduate Generalist’s Courses A Generalist’s Course Developed by the Mountain.
Medication-Assisted Treatment: What’s in the Cupboard and Why

Medication-Assisted Treatment: What’s in the Cupboard and Why
Buprenorphine in the treatment of addiction Matthew A. Torrington MD Clinical Research Physician UCLA: Integrated Substance Abuse Programs Matrix Institute.

Buprenorphine in the treatment of addiction Matthew A. Torrington MD Clinical Research Physician UCLA: Integrated Substance Abuse Programs Matrix Institute.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,

HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.

Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.

Similar presentations

Ads by Google